Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate Safety and Efficacy of BGB-3111, a Bruton's Tyrosine Kinase (BTK) Inhibitor in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Next Previous
X
Search
Trial Profile

A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate Safety and Efficacy of BGB-3111, a Bruton's Tyrosine Kinase (BTK) Inhibitor in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zanubrutinib (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors BeiGene

    • Most Recent Events

    • 08 Jul 2023 Results (from studies NCT03206918 and NCT03493217) assessing Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemiapublished in the Investigational New Drugs
    • 01 Mar 2023 Final results assessing safety and efficacy after extended follow-up and provide an update on the resistance study and exploratory correlative analysis of lymphocytosis on prognostic factors of chronic lymphocytic leukemia/small lymphocytic lymphoma, published in the Leukemia and Lymphoma.
    • 28 Jul 2022 Results of a pooled post-hoc analysis assessing long-term follow-up outcomes of zanubrutinib in various lines of therapy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma from following clinical studies: NCT03189524, NCT02343120 and NCT03206918 published in the Advances in Therapy

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top